ELIQUENT Life Sciences Joins EUR13 Million Horizon Europe Consortium to Advance Regulatory Development of Novel Osteoarthritis Therapy
· newswise.com · popularity 18/100 · 0 similar stories today · Cybersecurity (Technology & Consumer Electronics)
Read the original at newswise.com →
Summary
ELIQUENT Life Sciences, a global regulatory, quality and safety consulting firm, today announced its participation in ExoCordOA, a EUR13 million, five-year project funded by Horizon Europe and coordinated by Exogenus Therapeutics. The program is focused on advancing extracellular vesicle-enriched secretome therapies toward clinical use, initially in osteoarthritis.
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 11.